Ausgabe 1/2016
Inhalt (22 Artikel)
The brain tissue response to surgical injury and its possible contribution to glioma recurrence
Lauriane Hamard, David Ratel, Laurent Selek, François Berger, Boudewijn van der Sanden, Didier Wion
Pro-apoptotic and anti-angiogenic properties of the α /β-thujone fraction from Thuja occidentalis on glioblastoma cells
Angelo Torres, Yosselyn Vargas, Daniel Uribe, Cristian Carrasco, Cristian Torres, René Rocha, Carlos Oyarzún, Rody San Martín, Claudia Quezada
Cationizable lipid micelles as vehicles for intraarterial glioma treatment
Juliane Nguyen, Johann R. N. Cooke, Jason A. Ellis, Michael Deci, Charles W. Emala, Jeffrey N. Bruce, Irving J. Bigio, Robert M. Straubinger, Shailendra Joshi
Combined inhibition of vascular endothelial growth factor receptor signaling with temozolomide enhances cytotoxicity against human glioblastoma cells via downregulation of Neuropilin-1
Jungwhoi Lee, Eunsoo Kim, Seung-Wook Ryu, Chulhee Choi, Kyungsun Choi
MiR-519a functions as a tumor suppressor in glioma by targeting the oncogenic STAT3 pathway
Li Hong, Liu Ya-wei, Wang Hai, Zhou Qiang, Li Jun-jie, Annie Huang, Qi Song-tao, Lu Yun-tao
Preservation of KIT genotype in a novel pair of patient-derived orthotopic xenograft mouse models of metastatic pediatric CNS germinoma
Holly Lindsay, Yulun Huang, Yuchen Du, Frank K. Braun, Wan Yee Teo, Mari Kogiso, Lin Qi, Huiyuan Zhang, Sibo Zhao, Hua Mao, Frank Lin, Patricia Baxter, Jack M. Su, Keita Terashima, Laszlo Perlaky, Murali Chintagumpala, Adekunle Adesina, Ching C. Lau, D. Williams Parsons, Xiao-Nan Li
Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids
Eduard H. Panosyan, Joseph L. Lasky, Henry J. Lin, Albert Lai, Yang Hai, Xiuqing Guo, Michael Quinn, Stanley F. Nelson, Timothy F. Cloughesy, P. Leia Nghiemphu
Small increases in enhancement on MRI may predict survival post radiotherapy in patients with glioblastoma
Cecelia Elizabeth Gzell, Helen R. Wheeler, Philip McCloud, Marina Kastelan, Michael Back
Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study
Carlos Kamiya-Matsuoka, Asif M. Paker, Linda Chi, Ayda Youssef, Sudhakar Tummala, Monica E. Loghin
Recurrent glioblastoma: who receives tumor specific treatment and how often?
Rieke Steffens, Sabine Semrau, Godehard Lahmer, Florian Putz, Sebastian Lettmaier, Ilker Eyüpoglu, Michael Buchfelder, Rainer Fietkau
Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases
Yingmei Li, Wenying Pan, Ian D. Connolly, Sunil Reddy, Seema Nagpal, Stephen Quake, Melanie Hayden Gephart
Vestibular schwannoma and pituitary adenoma in the same patient: coincidence or novel clinical association?
Matthew L. Carlson, Neil S. Patel, Amy E. Glasgow, Elizabeth B. Habermann, Brandon R. Grossardt, Michael J. Link
Neuro-oncology family caregivers are at risk for systemic inflammation
Paula R. Sherwood, Thomas J. Price, Jason Weimer, Dianxu Ren, Heidi S. Donovan, Charles W. Given, Barbara A. Given, Richard Schulz, Jennifer Prince, Catherine Bender, Florien W. Boele, Anna L. Marsland
Management patterns of patients with cerebral metastases who underwent multiple stereotactic radiosurgeries
Deborah C. Marshall, Logan P. Marcus, Teddy E. Kim, Brandon A. McCutcheon, Steven J. Goetsch, Takao Koiso, John F. Alksne, Kenneth Ott, Bob S. Carter, Jona A. Hattangadi-Gluth, Masaaki Yamamoto, Clark C. Chen
Clinical features of subarachnoid hemorrhage in patients with positive cancer history
Ichiyo Shibahara, Takashi Watanabe, Masayuki Ezura, Takashi Inoue, Miki Fujimura, Naoto Kimura, Tomoo Inoue, Ichiro Suzuki, Akiko Nishino, Shinjitsu Nishimura, Hiroshi Uenohara, Teiji Tominaga
Pencil beam scanning proton therapy for pediatric intracranial ependymoma
Carmen Ares, Francesca Albertini, Martina Frei-Welte, Alessandra Bolsi, Michael A. Grotzer, Gudrun Goitein, Damien C. Weber
Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma
J. Duerinck, S. Du Four, F. Vandervorst, N. D’Haene, M. Le Mercier, A. Michotte, A. M. Van Binst, H. Everaert, I. Salmon, F. Bouttens, V. Verschaeve, B. Neyns
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study
Enrico Franceschi, Roberta Depenni, Alexandro Paccapelo, Mario Ermani, Marina Faedi, Carmelo Sturiale, Maria Michiara, Franco Servadei, Giacomo Pavesi, Benedetta Urbini, Anna Pisanello, Girolamo Crisi, Michele A. Cavallo, Claudio Dazzi, Claudia Biasini, Federica Bertolini, Claudia Mucciarini, Giuseppe Pasini, Agostino Baruzzi, Alba A. Brandes
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial
Mustafa Khasraw, Adrian Lee, Sally McCowatt, Zoltan Kerestes, Marc E. Buyse, Michael Back, Ganessan Kichenadasse, Stephen Ackland, Helen Wheeler
Comment on: the role of biopsy in the management of patients with presumed diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline
Christoph Schwartz, Friedrich-Wilhelm Kreth
Neuro-oncology biotech industry progress report
Shamik Chakraborty, Imithri Bodhinayake, Amrit Chiluwal, David J. Langer, Rosamaria Ruggieri, Marc Symons, John A. Boockvar
Erratum to: PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment
Dimitrios Mathios, Jacob Ruzevick, Christopher M. Jackson, Haiying Xu, Sagar R. Shah, Janis M. Taube, Peter C. Burger, Edward F. McCarthy, Alfredo Quinones-Hinojosa, Drew M. Pardoll, Michael Lim